Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IkT-001Pro bioequivalence study in healthy volunteers
NCT05623774Phase 1Completed
- Sponsor
- Inhibikase Therapeutics, Inc.
- Start
- Dec 2022
- Primary completion
- Jun 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of IKT-001 in chronic myeloid leukemia (CML) (5 arms), sponsored by Inhibikase Therapeutics, Inc. Primary endpoints: Area Under the Concentration-Time Curve from Time Zero to Last Measurable Concentration at 12 days, Area Under the Concentration-Time Curve from Time Zero to Infinity at 12 days and 3 more. Started Dec 2022; status: completed.
02
Drugs
IKT-001
03
Conditions
chronic myeloid leukemia (CML)
Beyond the preview
Go deeper on NCT05623774.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05623774.